| This week's sponsor is Premier Research. | | | ICH GCP guideline updates. Looking for the best insights?
The ICH Good Clinical Practice guidelines have been updated to reflect profound changes in how clinical trials run. Our white paper covers what you need to know. Premier Research. It's what we do. Best. |
Today's Rundown Redx pauses WNT cancer trial after first patient suffers adverse events Unum IPO hits bottom of range, netting $62M for cell therapy cancer trials MediciNova's repurposed stroke drug flops in methamphetamine dependence trial [Sponsored] Highlighting Women Pioneers in Science & Medicine U.K. biotech C4XD leaps on $294M addiction drug deal with Indivior Mitsubishi Tanabe, Hitachi join forces in AI-enabled clinical trials Abbott backs Bigfoot, bringing series B haul up to $55M Featured Story | | | Thursday, March 29, 2018 Redx has hit pause on a phase 1/2a trial of its porcupine inhibitor after the first patient to receive the drug suffered “clinically significant” adverse events. The blow continues a rotten run for Redx, which spent half of last year fighting to resolve a debt crisis. |
|
|
Top Stories Thursday, March 29, 2018 Unum Therapeutics has netted $62 million in a Nasdaq IPO. The total falls short of the amount Unum set out to raise but leaves the biotech with enough cash to advance two cell therapy candidates in four clinical trials. Thursday, March 29, 2018 MediciNova's repurposed stroke and asthma drug ibudilast missed its primary endpoint of methamphetamine abstinence in a 12-week phase 2 trial. Monday, March 26, 2018 As leaders in science and business, two high-profile female CEOs have been instrumental in advancing medical breakthroughs and are champions for issues that affect women around the world. Thursday, March 29, 2018 Shares in U.K. biotech C4X Discovery almost doubled today after Reckitt Benkiser spinout Indivior agreed a $294 million deal for a drug candidate to treat addiction. Thursday, March 29, 2018 Through a new collaboration, Mitsubishi Tanabe Pharma will apply Hitachi’s artificial intelligence technology to make clinical trials more efficient and to drive down drug development costs. Thursday, March 29, 2018 Abbott has participated in diabetes startup Bigfoot Biomedical’s series B round. The involvement of Abbott and other investors means Bigfoot has $55 million to take its insulin pump and pen through clinical development and onto the market. Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA Understanding Drug Pricing and Reimbursement April 3,2018 | Washington, DC IRT Europe – Interactive Response Technologies in Clinical Trials April 10th-11th, 2018 | Brussels, Belgium Field Service USA 2018 April 17-April 20, 2018 | JW Marriott Palm Desert Resort & Spa, CA
Drug Development Immersion April 25-26, 2018 | New York City Biotech for the Non-Scientist May 2-3, 2018 | San Diego, CA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Immersion May 17-18, 2018 | Boston, MA BIO International Convention June 4-7, 2018 | Boston, MA
BioBasics: Biotech for the Non-Scientist June 13 - 14, 2018 | Toronto, Canada BioBasics: Biotech for the Non-Scientist June 13 - 14, 2018 | West Windsor, NJ Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 